A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation

Background: The rivaroxaban dose regimen for patients with nonvalvular atrial fibrillation (NVAF) is complex in Asia. Given the high interindividual variability and the risk of bleeding caused by rivaroxaban in Asians, the influencing factors and the relationship between outlier biomarkers and bleed...

Full description

Bibliographic Details
Main Authors: Nan Zhao, Zhiyan Liu, Qiufen Xie, Zhe Wang, Zhongyi Sun, Qian Xiang, Yimin Cui
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Pharmacology
Subjects:
anti-xa activity
prothrombin time
bleeding
Chinese
population pharmacokinetics
PK/PD
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.814724/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.814724/full

Similar Items